HK9926 chance to breakout from its long term range?

2024年9月16日

With its oversea partner (US.SMMT) breakout and achieve 10x in a year, I think HK9926 is likely to breakout and extend its range, to form a leg, from current long term range.

HK9926 still have momentum and see if it can breakout through this momentum, I think currently is still a buy.
There are still some catalyst coming this september and see if it can hold this current price range above $60.

But I won't chace SMMT as it is over-extended in weekly timeframe and could experience a retracement.

3月20日

註釋

after a range bound for some while, is this going to be a trend continuation?

4月1日

註釋

Trend continuation now, the earnings result are really good, CEO is positive about its AK112 to become the best-in-class drug in its field globally. sq&nsq NSCLC, MSSmCRC are big market, it can compete with Keytruda. Also If NSCLC test coming out in mid-year is positive, it could apply for US FDA and sell globally, not just in China.